View Article

Abstract

The groundbreaking TEMPO 3:4 trial, which served as the basis for tolvaptan's approval, represented a revolution in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Through this advancement, patient management for ADPKD has evolved from using broad strategies to stop the progression of chronic kidney disease to focusing on disease-specific mechanisms. Evidence-based strategies to start treatment only in patients with quickly worsening disease are essential, though, given the long-term nature of this medication and associated side effects. The European Renal Association (ERA) policy statement, released in 2016, was the first society-based guideline on the usage of tolvaptan and has been a popular resource for nephrologists when making decisions. Since then, there has been a significant accumulation of practical knowledge regarding the use of tolvaptan in ADPKD.

Keywords

ADPKD; polycystic kidney disease; position statement; tolvaptan; vasopressin V2 receptor antagonist

Reference

  1. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24(6):1601–1608.
  2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med. 2007;120(11A):S1–S21. 
  3. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2009. Samsca (tolvaptan), package insert. 
  4. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112.
  5. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343.
  6. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  7. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112. 
  8. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  9. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  10. Structure of Tolvaptan - https://web.chemdoodle.com/demos/iupac-naming#customise-template
  11. Indian Pharmacopoeia - 2022,  Ninth Edition, Volume – III, Page number: 3832, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, Andhra Pradesh, India.

Photo
Kondeti Venkata Surya Siva Kumar
Corresponding author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Latha Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Jaya Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Kondeti Venkata Surya Siva Kumar, Saripella Latha Sree and Saripella Jaya Sree, Tolvaptan - Vasopressin Antagonist for Hyponatremia, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 8, 1-8. https://doi.org/10.5281/zenodo.8206257

More related articles
Formulation And In-Vitro Evaluation of Compression...
Ayesha Sultana , H. Doddayya, Soukhya Joshi G., Saqib Akram Wani,...
Hereditary Breast and Ovarian Cancer Driven by BRC...
Varaganti Sai Chitra Prathyusha, Lalatendu Mohanty, Pallavi, Apur...
Smart Nanocarriers for Targeted Drug Delivery in Cancer Therapy: Recent Advances...
Sachin Adsule, Mayuri Bhadalekar, Dr. Nilesh Chougule, ...
Type 2 Diabetes Mellitus: An Overview of Pathophysiology, Current Management, an...
Sujit Ninayade, Shivani Kumbhar, Sainath Rathod, Nasreen Shaikh, Sonali Patil, ...
Related Articles
Management Of Avascular Necrosis Through Ayuveda: A Case Study...
Raja Singla, Prerna Sharma , Narender Kumar, ...
Butterfly Pea (Clitoria ternatea): A Versatile Medicinal Plant with Multifaceted...
Pooja Rajude, Vikram Saruk, Purva Deshmukh, Ramdas Darade, ...
Overview On The Novel Medication Of Liquisolid Technology For Improving Solubili...
Desai Avni P., Krishna P. Vairagi, Dhruvi B. Parmar, Heli H. Desai, ...
A Review: Nanotechnology as a Novel Drug Delivery System...
Prince Raj , Sushma T. Nakhate, Dr. Tushar Treembak Shelke, ...
Formulation And In-Vitro Evaluation of Compression Coated Core Tablets of Metron...
Ayesha Sultana , H. Doddayya, Soukhya Joshi G., Saqib Akram Wani, Sushma, Touseef, Vanishree K., Pra...
More related articles
Formulation And In-Vitro Evaluation of Compression Coated Core Tablets of Metron...
Ayesha Sultana , H. Doddayya, Soukhya Joshi G., Saqib Akram Wani, Sushma, Touseef, Vanishree K., Pra...
Hereditary Breast and Ovarian Cancer Driven by BRCA1/BRCA2 Variants: Chromosomal...
Varaganti Sai Chitra Prathyusha, Lalatendu Mohanty, Pallavi, Apurwa Ekhankar, Snehal Shingade, Tanya...
Formulation And In-Vitro Evaluation of Compression Coated Core Tablets of Metron...
Ayesha Sultana , H. Doddayya, Soukhya Joshi G., Saqib Akram Wani, Sushma, Touseef, Vanishree K., Pra...
Hereditary Breast and Ovarian Cancer Driven by BRCA1/BRCA2 Variants: Chromosomal...
Varaganti Sai Chitra Prathyusha, Lalatendu Mohanty, Pallavi, Apurwa Ekhankar, Snehal Shingade, Tanya...